Every year, sponsors hesitating to use a complex innovative clinical trial design routinely miss opportunities to optimize the speed, savings and probability of success of their clinical trials. Clinical trials with complex advanced innovative designs use adaptive methods, Bayesian methods and other novel clinical trial design techniques to increase efficiency and reduce costs.
Both large pharmaceutical companies and small biotechs can benefit from innovative trial designs as they aid in improved clinical development, better pre-planning, greater patient safety, less medical waste, and/or increased knowledge. These designs enable researchers to mitigate uncertainty by pre-planning ways to adapt as they learn. They are also very helpful in dealing with uncertainty and the variability in the data that is collected during clinical trials.
Cytel have achieved 100% regulatory acceptance of all adaptive clinical trial proposals. Our statisticians are leading experts in the complex design of adaptive Bayesian design, adaptive promising zone designs, adaptive enrichment clinical trials, basket trials, umbrella trials and more.
In an interview with International Clinical Trials (ICT) Magazine, Cytel’s Chief Scientific Officer, Yannis Jemiai discusses the evolution and impact of Bayesian and adaptive clinical trial designs. Yannis talks about how the pandemic made the adoption of these innovative designs necessary and why their use is likely to increase post-pandemic.